Omnigen and Toxys have received an MIT grant for the development and extension of the ToxPlot software. With this grant, the ToxPlot analysis tool will be further developed to allow quantitative and hypothesis-free toxicity profiling of novel chemicals. Currently, ToxPlot is primarily used as an in-house tool at Toxys for data-analysis of ToxTracker results.
ToxTracker is Toxys’ unique animal-free test system for identification of potentially carcinogenic properties of novel chemicals. ToxTracker combines multiple biomarkers to get mechanistic insight into the of action of (geno)toxic compounds. The essay not only includes markers for DNA damage but also for a non-genotoxic mode of action, including oxidative stress, protein misfolding and cytotoxicity. The combination of multiple biomarkers results in a rich dataset and an extensive toxicological profile of the tested compounds.
Scheduled developments of ToxPlot
With the MIT grant, Toxplot will be further developed into a software platform that can be used by toxicology laboratories in the pharmaceutical, chemical and cosmetics industry. The developed ToxPlot software package will consist of:
- ToxPlot analysis tools for hypothesis-free data mining and analysis of the rich datasets obtained by ToxTracker.
- A ToxTracker database containing extensive (geno)toxicity data from a large set of reference compounds.
- Quantitative modelling and visualisation modules for quantitative analysis of the toxic properties of compounds to improve human risk assessment.
This project combines the innovative in vitro toxicity screening tool developed by Toxys and the unique bioinformatics expertise at Omnigen. The combination of these disciplines will allow users to extract the most information from the biological data, thus adding value and insight into how their compounds respond.
Omnigen’s experience in working with genetic data and developing analysis tools is essential to deliver a user-friendly software package with the necessary analytical power to get the most information out of the rich data sets generated by using ToxTracker. This will allow Toxys to offer the ToxPlot software together with a licensing option to their unique ToxTracker assay.
Omnigen is a dynamic Dutch ICT company with unique expertise in bio-informatics, big-data and genomics which is being applied to the Life Science sector. Omnigen has developed products that used genetics data to provide athletes with advice on training and nutrition based on their unique genetic profiles. As of 2018 Omnigen will focus on applying its expertise in clinical biomarker discovery and clinical diagnostics.
Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing.
Please contact us if you have any questions via:
+31(0)85-04 33 222